Pharma industry spending on lobbying exploded in 2018

The trade group for the U.S.'s top drugmakers spent a record amount––$27.5 million––on lobbying efforts in 2018, according to Bloomberg.

The spending, which was disclosed by the Pharmaceutical Research and Manufacturers of America (PhRMA), was $1.4 million more than what was reported in 2009, when the Affordable Care Act was crafted. The association spent nearly $10 million during the first three months of 2018 to lobby Congress and the Trump administration—its biggest-ever quarter, Bloomberg reported. More than $6 million was spent on lobbying efforts in the fourth quarter of 2018.

The spending surge was a reaction to the potentially “most challenging year in decades” for the industry.

The lobbying disclosure comes at a time when rising drug prices have garnered negative attention from President Trump, lawmakers and consumers. For example, the cost of managing diabetes has increased significantly from 2012 to 2016, according to a recent report.

The Trump administration has ramped up efforts to lower drug prices, while House Democrats launched an investigation into rising prices.

See the full story below:  

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup